ACADIA Pharmaceuticals Earnings Estimate
| ACAD Stock | USD 23.20 0.25 1.09% |
ACADIA Pharmaceuticals Earnings Estimation Breakdown
The calculation of ACADIA Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of ACADIA Pharmaceuticals is estimated to be 0.1944 with the future projection ranging from a low of 0.09 to a high of 0.2875. Please be aware that this consensus of annual earnings estimates for ACADIA Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.09 Lowest | Expected EPS | 0.29 Highest |
ACADIA Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of ACADIA Pharmaceuticals' value are higher than the current market price of the ACADIA Pharmaceuticals stock. In this case, investors may conclude that ACADIA Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and ACADIA Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 20 | 67.27% | 0.0 | 0.1944 | 1.62 |
ACADIA Pharmaceuticals Earnings per Share Projection vs Actual
Actual Earning per Share of ACADIA Pharmaceuticals refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering ACADIA Pharmaceuticals predict the company's earnings will be in the future. The higher the earnings per share of ACADIA Pharmaceuticals, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.ACADIA Pharmaceuticals Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as ACADIA Pharmaceuticals, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of ACADIA Pharmaceuticals should always be considered in relation to other companies to make a more educated investment decision.ACADIA Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact ACADIA Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 | ||
2025-11-05 | 2025-09-30 | 0.14 | 0.42 | 0.28 | 200 | ||
2025-08-07 | 2025-06-30 | 0.14 | 0.16 | 0.02 | 14 | ||
2025-05-06 | 2025-03-31 | 0.05 | 0.11 | 0.06 | 120 | ||
2025-02-25 | 2024-12-31 | 0.219 | 0.86 | 0.641 | 292 | ||
2024-11-06 | 2024-09-30 | 0.14 | 0.2 | 0.06 | 42 | ||
2024-08-06 | 2024-06-30 | 0.18 | 0.2 | 0.02 | 11 | ||
2024-05-08 | 2024-03-31 | 0.05 | 0.1 | 0.05 | 100 | ||
2024-02-27 | 2023-12-31 | 0.3 | 0.28 | -0.02 | 6 | ||
2023-11-02 | 2023-09-30 | -0.43 | -0.4 | 0.03 | 6 | ||
2023-08-02 | 2023-06-30 | -0.08 | 0.01 | 0.09 | 112 | ||
2023-05-08 | 2023-03-31 | -0.21 | -0.27 | -0.06 | 28 | ||
2023-02-27 | 2022-12-31 | -0.24 | -0.26 | -0.02 | 8 | ||
2022-11-02 | 2022-09-30 | -0.19 | -0.17 | 0.02 | 10 | ||
2022-08-08 | 2022-06-30 | -0.25 | -0.21 | 0.04 | 16 | ||
2022-05-04 | 2022-03-31 | -0.6 | -0.33 | 0.27 | 45 | ||
2022-02-28 | 2021-12-31 | -0.24 | -0.27 | -0.03 | 12 | ||
2021-11-08 | 2021-09-30 | -0.26 | -0.09 | 0.17 | 65 | ||
2021-08-04 | 2021-06-30 | -0.3 | -0.27 | 0.03 | 10 | ||
2021-05-05 | 2021-03-31 | -0.53 | -0.42 | 0.11 | 20 | ||
2021-02-24 | 2020-12-31 | -0.47 | -0.42 | 0.05 | 10 | ||
2020-11-04 | 2020-09-30 | -0.38 | -0.54 | -0.16 | 42 | ||
2020-08-05 | 2020-06-30 | -0.44 | -0.27 | 0.17 | 38 | ||
2020-05-07 | 2020-03-31 | -0.48 | -0.57 | -0.09 | 18 | ||
2020-02-26 | 2019-12-31 | -0.36 | -0.34 | 0.02 | 5 | ||
2019-10-30 | 2019-09-30 | -0.4 | -0.29 | 0.11 | 27 | ||
2019-07-31 | 2019-06-30 | -0.45 | -0.38 | 0.07 | 15 | ||
2019-05-01 | 2019-03-31 | -0.52 | -0.59 | -0.07 | 13 | ||
2019-02-26 | 2018-12-31 | -0.55 | -0.5 | 0.05 | 9 | ||
2018-11-06 | 2018-09-30 | -0.58 | -0.5 | 0.08 | 13 | ||
2018-08-08 | 2018-06-30 | -0.45 | -0.51 | -0.06 | 13 | ||
2018-05-04 | 2018-03-31 | -0.55 | -0.44 | 0.11 | 20 | ||
2018-02-27 | 2017-12-31 | -0.58 | -0.55 | 0.03 | 5 | ||
2017-11-07 | 2017-09-30 | -0.62 | -0.53 | 0.09 | 14 | ||
2017-08-08 | 2017-06-30 | -0.72 | -0.55 | 0.17 | 23 | ||
2017-05-09 | 2017-03-31 | -0.73 | -0.72 | 0.01 | 1 | ||
2017-02-28 | 2016-12-31 | -0.65 | -0.65 | 0.0 | 0 | ||
2016-11-07 | 2016-09-30 | -0.56 | -0.61 | -0.05 | 8 | ||
2016-08-04 | 2016-06-30 | -0.49 | -0.63 | -0.14 | 28 | ||
2016-05-05 | 2016-03-31 | -0.42 | -0.45 | -0.03 | 7 | ||
2016-02-29 | 2015-12-31 | -0.38 | -0.45 | -0.07 | 18 | ||
2015-11-05 | 2015-09-30 | -0.4 | -0.39 | 0.01 | 2 | ||
2015-08-06 | 2015-06-30 | -0.33 | -0.39 | -0.06 | 18 | ||
2015-05-07 | 2015-03-31 | -0.27 | -0.4 | -0.13 | 48 | ||
2015-02-26 | 2014-12-31 | -0.26 | -0.28 | -0.02 | 7 | ||
2014-11-10 | 2014-09-30 | -0.22 | -0.25 | -0.03 | 13 | ||
2014-08-05 | 2014-06-30 | -0.19 | -0.22 | -0.03 | 15 | ||
2014-05-06 | 2014-03-31 | -0.13 | -0.19 | -0.06 | 46 | ||
2014-02-27 | 2013-12-31 | -0.13 | -0.13 | 0.0 | 0 | ||
2013-11-06 | 2013-09-30 | -0.12 | -0.12 | 0.0 | 0 | ||
2013-08-06 | 2013-06-30 | -0.09 | -0.11 | -0.02 | 22 | ||
2013-05-07 | 2013-03-31 | -0.08 | -0.08 | 0.0 | 0 | ||
2013-03-12 | 2012-12-31 | -0.09 | -0.11 | -0.02 | 22 | ||
2012-11-05 | 2012-09-30 | -0.09 | -0.04 | 0.05 | 55 | ||
2012-08-08 | 2012-06-30 | -0.12 | -0.1 | 0.02 | 16 | ||
2012-05-08 | 2012-03-31 | -0.11 | -0.12 | -0.01 | 9 | ||
2012-03-06 | 2011-12-31 | -0.1 | -0.1 | 0.0 | 0 | ||
2011-11-09 | 2011-09-30 | -0.1 | -0.1 | 0.0 | 0 | ||
2011-08-10 | 2011-06-30 | -0.14 | -0.12 | 0.02 | 14 | ||
2011-05-10 | 2011-03-31 | -0.11 | -0.12 | -0.01 | 9 | ||
2011-03-10 | 2010-12-31 | 0.69 | 0.74 | 0.05 | 7 | ||
2010-11-09 | 2010-09-30 | -0.17 | -0.11 | 0.06 | 35 | ||
2010-08-09 | 2010-06-30 | -0.16 | -0.11 | 0.05 | 31 | ||
2010-05-10 | 2010-03-31 | -0.17 | -0.14 | 0.03 | 17 | ||
2010-03-09 | 2009-12-31 | -0.19 | -0.2 | -0.01 | 5 | ||
2009-11-09 | 2009-09-30 | -0.24 | -0.23 | 0.01 | 4 | ||
2009-08-05 | 2009-06-30 | -0.34 | -0.34 | 0.0 | 0 | ||
2009-05-11 | 2009-03-31 | -0.36 | -0.4 | -0.04 | 11 | ||
2009-03-09 | 2008-12-31 | -0.37 | -0.38 | -0.01 | 2 | ||
2008-11-05 | 2008-09-30 | -0.45 | -0.42 | 0.03 | 6 | ||
2008-08-05 | 2008-06-30 | -0.46 | -0.49 | -0.03 | 6 | ||
2008-05-05 | 2008-03-31 | -0.46 | -0.44 | 0.02 | 4 | ||
2008-03-05 | 2007-12-31 | -0.46 | -0.46 | 0.0 | 0 | ||
2007-11-05 | 2007-09-30 | -0.38 | -0.43 | -0.05 | 13 | ||
2007-08-06 | 2007-06-30 | -0.39 | -0.29 | 0.1 | 25 | ||
2007-05-08 | 2007-03-31 | -0.43 | -0.42 | 0.01 | 2 | ||
2007-03-06 | 2006-12-31 | -0.44 | -0.42 | 0.02 | 4 | ||
2006-11-06 | 2006-09-30 | -0.4 | -0.38 | 0.02 | 5 | ||
2006-08-08 | 2006-06-30 | -0.36 | -0.43 | -0.07 | 19 | ||
2006-05-10 | 2006-03-31 | -0.35 | -0.39 | -0.04 | 11 | ||
2006-03-01 | 2005-12-31 | -0.38 | -0.44 | -0.06 | 15 | ||
2005-11-10 | 2005-09-30 | -0.3 | -0.53 | -0.23 | 76 | ||
2005-08-10 | 2005-06-30 | -0.29 | -0.26 | 0.03 | 10 | ||
2005-05-11 | 2005-03-31 | -0.4 | -0.31 | 0.09 | 22 | ||
2005-03-03 | 2004-12-31 | -0.41 | -0.44 | -0.03 | 7 | ||
2004-11-10 | 2004-09-30 | -0.37 | -0.37 | 0.0 | 0 | ||
2004-08-11 | 2004-06-30 | -0.66 | -0.42 | 0.24 | 36 |
About ACADIA Pharmaceuticals Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of ACADIA Pharmaceuticals earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current ACADIA Pharmaceuticals estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as ACADIA Pharmaceuticals fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -2 B | -1.9 B | |
| Retained Earnings Total Equity | -1.9 B | -1.8 B | |
| Earnings Yield | 0.07 | 0.07 | |
| Price Earnings Ratio | 15.44 | 16.21 | |
| Price Earnings To Growth Ratio | (0.03) | (0.03) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ACADIA Pharmaceuticals is a strong investment it is important to analyze ACADIA Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ACADIA Pharmaceuticals' future performance. For an informed investment choice regarding ACADIA Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ACADIA Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Will Biotechnology sector continue expanding? Could ACADIA diversify its offerings? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every ACADIA Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 1.128 | Earnings Share 1.62 | Revenue Per Share | Quarterly Revenue Growth 0.113 | Return On Assets |
The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that ACADIA Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether ACADIA Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, ACADIA Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.